Largest healthcare initiative of its kind in Canada launched to conquer cancer in our lifetime TORONTO, April 12, 2012 /PRNewswire/ - Amidst the skirl of the pipes and a

TORONTO, April 3, 2012 /PRNewswire/ -- Mobile Integrated Systems, Inc (OTCBB:LOTID), operating through its wholly-owned subsidiary Mobilotto Systems, Inc.

A second, larger clinical research study led by breast cancer specialists at Princess Margaret Hospital (PMH) has again proven that comparing a new biopsy of progressing or recurring cancer with that of the original cancer can dictate a change in treatment.

Cancer researchers at Princess Margaret Hospital (PMH) have discovered that targeting an enzyme called Uroporphyrinogen Decarboxylase (UROD) can sensitize diseased tissue to radiation and chemotherapy, which could mean fewer side effects for individuals with head and neck cancer.

Dr. John Dick, Senior Scientist at the Ontario Cancer Institute, the research arm of Princess Margaret Hospital, co-led a multinational team that has developed the first leukemia therapy that targets a protein, CD123, on the surface of cancer stem cells that drive acute myeloid leukemia (AML), which is an aggressive disease with a poor outcome.